Sylentis ( Grupo Pharmamar) : ¡¡ SEGUIMOS TRABAJANDO!! .

13,45 , FRIDAY 15 NOVEMBER 2019 . Anne-Marie Bleau, Ph.D., Clinical Operations Manager, Sylentis, Spain.

Anne-Marie Bleau obtuvo su Ph.D. en farmacología en la Universidad de Montreal en 2002. Realizó una formación posdoctoral en la Universidad Paris 7 (2002-2005) y luego se unió al Centro de Cáncer Memorial Sloan-Kettering, Nueva York (2006-2009) para estudiar las células madre del cáncer. . Ella incorporó el Centro de Investigación Médica Aplicada (Pamplona, ​​2010-2014) como investigador colaborativo, que fue apoyado por una beca internacional Marie Curie. Trabajó como investigadora clínica en la Clínica Universidad de Navarra (Pamplona) durante 2 años en el Departamento de Oftalmología. Actualmente trabaja en Sylentis (España) como Gerente de Operaciones Clínicas.

PharmaMar . Agenda Semanal .

PharmaMar Group Presentará está Semana :

*.- Datos del Yondelis en Japón .

*.- Datos del Tivanisirán en Holanda .

*.- Datos del Zepsyre en EEUU .

Mesothelioma . Promising Results for Second-Line . Lurbinectedin Could be the Next Step for Some .

Tratamiento de Segunda Línea para el Mesotelioma con ZEPSYRE® ( Lurbinectedin ).

13 de Noviembre de 2019. Alex Strauss .

Swiss researchers may have finally found an effective second-line treatment for mesothelioma.

Scientists with the Swiss Group for Clinical Cancer Research presented their findings at the recent European Society for Medical Oncology conference in Barcelona.

Mesothelioma patients who fail after first-line therapy have few options. The new study focused on lurbinectedin, a drug that impacts cancer cells at the DNA level. Early studies suggest lurbinectedin might make a good second-line treatment for small cell lung cancer.

According to the Swiss team, more than half of patients in their study responded to lurbinectedin as a second-line treatment for mesothelioma.

In Search of a Second-Line Mesothelioma Treatment .

Malignant mesothelioma is notoriously difficult to diagnose and even harder to treat. It is usually caused by occupational exposure to asbestos. Once asbestos fibers enter the lungs, they stay there indefinitely. Patients can develop mesothelioma even decades after they are exposed.

Once the symptoms of mesothelioma develop, even the best standard treatments may not help much. Only about 40 percent of patients respond to chemotherapy. Those who do usually see a return of their cancer within a few months.

After patients have exhausted first-line therapies, there is no standard second-line treatment for mesothelioma. Some studies show retreatment with chemotherapy can slow the disease down. But researchers around the world are trying to find other, more effective ways to improve mesothelioma survival.

Lurbinectedin Could be the Next Step for Some .

Lurbinectedin is an oncogenic transcription inhibitor. According to the National Cancer Institute drug dictionary, it “binds to residue lying in the minor groove of DNA”. This keeps cancer cells from progressing through their normal life phases and may cause them to die early.

The Swiss study of lurbinectedin as a second-line treatment for mesothelioma involved 42 patients. The patients previously received either chemotherapy alone or chemotherapy with immunotherapy. Every patient had eventually relapsed.

Study subjects received 3.2 mg/m2 of lurbinectedin every 3 weeks until their cancer progressed. Researchers had a goal to stop mesothelioma progression for at least 12 weeks in at least 21 patients.

Promising Results for Second-Line Treatment for Mesothelioma.

“At cut-off date, progression free survival was met by 22/42 patients,” reported presenter Yannis Metaxas. “One patient had complete, one patient partial response, and 20 patients stable disease as best response.”

Among the patients who responded to lurbinectedin as a second-line treatment for mesothelioma, it took a median of four months for their tumors to grow again. Overall survival in the group was about a year.

Other second- and third-line mesothelioma treatments are not as effective. Median progression-free survival with other options is less than two months. Overall survival with every other second-line treatment for mesothelioma is six to nine months.

But lurbinectedin is not problem-free. Most patients had some complications. A drop in white blood cells and fatigue were the most common issues.

The researchers say the study is a good start, but more work is needed. “Respective patient numbers are small for definitive conclusions,” writes Dr. Metaxas. “Further evaluation of lurbinectedin in a large randomized trial is warranted.”

El ICO registra una de las mejores tasas de supervivencia en cáncer del mundo .

Barcelona, 13 nov (EFE).-

Las tasas de supervivencia de los enfermos de cáncer de recto, ovario y pulmón tratados en el Instituto Catalán de Oncología (ICO) se mantienen entre las más altas del mundo, según el balance presentado este miércoles por el centro.

Según datos del ICO, Cataluña se encuentra entre las regiones con las tasas de curación del cáncer más elevadas del mundo y los incrementos de supervivencia a 5 años han pasado del 48,8 % al 54 % en hombres y del 59,9 % al 62,5 % en mujeres.

...

Un nuevo método de cribado no invasivo de cáncer de colon podría evitar un 35% de las colonoscopias que se realizan .

*.- La colonoscopia se realiza a quienes dan positivo en los métodos de cribado.

*.- Esta nueva técnica podría elevar la precisión de un 70% a un 96%.

13.11.2019 .

Investigadores del Hospital Clínic-IDIBAPS de Barcelona han desarrollado un método de cribado no invasivo que mejora la detección precoz del cáncer de colon y podría evitar el 35 % de colonoscopias que se hacen ahora tras dar un falso positivo con el actual cribado.


Los científicos proponen añadir su propuesta al actual cribado, que busca sangre en las heces: el análisis de dos microRNA (pequeñas moléculas de RNA o ácido ribonucleico) que permiten distinguir los pacientes con cáncer de colon o adenomas avanzados de los que no tienen lesiones.

...